Aprinoia Therapeutics (Aprinoia Therapeutics) EV-to-Revenue : 0.00 (As of Apr. 26, 2024)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aprinoia Therapeutics's enterprise value is $0.00 Mil. Aprinoia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $9.13 Mil. Therefore, Aprinoia Therapeutics's EV-to-Revenue for today is 0.00.

The historical rank and industry rank for Aprinoia Therapeutics's EV-to-Revenue or its related term are showing as below:

APRI's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.68
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Aprinoia Therapeutics's stock price is $0.00. Aprinoia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.33. Therefore, Aprinoia Therapeutics's PS Ratio for today is 0.00.

Aprinoia Therapeutics EV-to-Revenue Historical Data

The historical data trend for Aprinoia Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics EV-to-Revenue Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

EV-to-Revenue

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
EV-to-Revenue	-	-	-	-

Competitive Comparison of Aprinoia Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Aprinoia Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's EV-to-Revenue falls into.

Aprinoia Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aprinoia Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.000	/	9.133
	=	0.00

Aprinoia Therapeutics's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $9.13 Mil.

Aprinoia Therapeutics (NAS:APRI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aprinoia Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.00	/	0.329
	=	0.00

Aprinoia Therapeutics's share price for today is $0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was $0.33.

Aprinoia Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines